Current Concepts of Dermatitis Herpetiformis

Acta Derm Venereol. 2020 Feb 12;100(5):adv00056. doi: 10.2340/00015555-3401.

Abstract

Dermatitis herpetiformis (DH) is an autoimmune skin disease that causes itchy, blistering rash, typically on the elbows, knees and buttocks. DH and coeliac disease share the same genetic background, gluten-dependent enteropathy and antibody response against tissue transglutaminase. DH is currently considered a cutaneous manifestation of coeliac disease, and the prevailing hypothesis is that DH develops as a late manifestation of subclinical coeliac disease. The incidence of DH is decreasing contemporarily with the increasing incidence of coeliac disease. The IgA immune response in DH skin is directed against epidermal transglutaminase, while the autoantigen in the gut is tissue transglutaminase. Granular IgA deposition in the papillary dermis is pathognomonic for DH, and is a finding used to confirm the diagnosis. The treatment of choice for DH is a life-long gluten-free diet, which resolves the rash and enteropathy, increases quality of life, and offers a good long-term prognosis.

Keywords: coeliac disease; gluten-free diet; immunoglobulin A; transglutaminase; villous atrophy; dermatitis herpetiformis.

Publication types

  • Review

MeSH terms

  • Autoimmune Diseases / epidemiology*
  • Autoimmune Diseases / immunology
  • Autoimmune Diseases / physiopathology
  • Autoimmune Diseases / therapy
  • Celiac Disease / epidemiology*
  • Celiac Disease / immunology*
  • Celiac Disease / physiopathology
  • Celiac Disease / therapy
  • Combined Modality Therapy
  • Comorbidity
  • Dapsone / administration & dosage*
  • Dermatitis Herpetiformis / epidemiology*
  • Dermatitis Herpetiformis / immunology
  • Dermatitis Herpetiformis / therapy*
  • Diet, Gluten-Free
  • Female
  • Humans
  • Incidence
  • Male
  • Prognosis
  • Risk Assessment
  • Transglutaminases / metabolism
  • Treatment Outcome

Substances

  • Dapsone
  • Transglutaminases